期刊文献+
共找到16篇文章
< 1 >
每页显示 20 50 100
Hepatitis B virus and hepatitis C virus dual infection 被引量:22
1
作者 Gaia Caccamo Francesca Saffioti Giovanni Raimondo 《World Journal of Gastroenterology》 SCIE CAS 2014年第40期14559-14567,共9页
Hepatitis B virus(HBV)and hepatitis C virus(HCV)share common mode of transmission and both are able to induce a chronic infection.Dual HBV/HCV chronic coinfection is a fairly frequent occurrence,especially in high end... Hepatitis B virus(HBV)and hepatitis C virus(HCV)share common mode of transmission and both are able to induce a chronic infection.Dual HBV/HCV chronic coinfection is a fairly frequent occurrence,especially in high endemic areas and among individuals at high risk of parenterally transmitted infections.The intracellular interplay between HBV and HCV has not yet been sufficiently clarified,also due to the lack of a proper in vitro cellular model.Longitudinal evaluation of serum HBV DNA and HCV RNA amounts has revealed that complex virological profiles may be present in coinfected patients.Dual HBV/HCV infection has been associated to a severe course of the liver disease and to a high risk of developing hepatocellular carcinoma.Despite the clinical importance,solid evidence and clear guidelines for treatment of this special population are still lacking.This review summarizes the available data on the virological and clinical features as well as the therapeutic options of the dual HBV/HCV infection,and highlights the aspects that need to be better clarified. 展开更多
关键词 hepatitis b virus/hepatitis C virus coinfection Chronic hepatitis Viral interaction CIRRHOSIS Hepatocellular carcinoma Antiviral therapy
下载PDF
Persistent occult hepatitis B virus infection:Experimental findings and clinical implications 被引量:17
2
作者 Patricia M Mulrooney-Cousins Tomasz I Michalak 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第43期5682-5686,共5页
Hepatitis B virus (HBV) is a highly pathogenic virus that causes chronic liver diseases in millions of people globally. In addition to a symptomatic, serologically evident infection, occult persistent HBV carriage has... Hepatitis B virus (HBV) is a highly pathogenic virus that causes chronic liver diseases in millions of people globally. In addition to a symptomatic, serologically evident infection, occult persistent HBV carriage has been identified since nucleic acid amplification assays of enhanced sensitivity became introduced for detection of hepadnaviral genomes and their replicative intermediates. Current evidence indicates that occult HBV infection is a common and long-term consequence of resolution of acute hepatitis B. This form of residual infection is termed as secondary occult infection (SOI). The data from the woodchuck model of HBV infection indicate that exposure to small amounts of hepadnavirus can also cause primary occult infection (POI) where virus genome, but no serological makers of exposure to virus, are detectable, and the liver may not be involved. However, virus replicates at low levels in the lymphatic system in both these forms. We briefly summarize the current understanding of the nature and characteristics of occult hepadnaviral persistence as well as of its documented and expected pathological consequences. 展开更多
关键词 hepatitis b viWoodchuck hepatitis virus Hepadnaviruses Hepadnaviral hepatitis Occult viral persistence Hepadnavirus lymphotropism Primary occult infection Secondary occult infection virus reactivation
下载PDF
Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic 被引量:4
3
作者 Caterina Sagnelli Mariantonietta Pisaturo +3 位作者 Caterina Curatolo Alessio Vinicio Codella Nicola Coppola Evangelista Sagnelli 《World Journal of Gastroenterology》 SCIE CAS 2021年第42期7271-7284,共14页
Hepatitis D virus(HDV)is a defective liver-tropic virus that needs the helper function of hepatitis B virus(HBV)to infect humans and replicate.HDV is transmitted sexually or by a parenteral route,in co-infection with ... Hepatitis D virus(HDV)is a defective liver-tropic virus that needs the helper function of hepatitis B virus(HBV)to infect humans and replicate.HDV is transmitted sexually or by a parenteral route,in co-infection with HBV or by super-infection in HBV chronic carriers.HDV infection causes acute hepatitis that may progress to a fulminant form(7%-14%by super-infection and 2%-3%by HBV/HDV co-infection)or to chronic hepatitis(90%by HDV super-infection and 2%-5%by HBV/HDV co-infection),frequently and rapidly progressing to cirrhosis or hepatocellular carcinoma(HCC).Peg-interferon alfa the only recommended therapy,clears HDV in only 10%-20%of cases and,consequently,new treatment strategies are being explored.HDV endemicity progressively decreased over the 50 years from the identification of the virus,due to improved population lifestyles and economic levels,to the use of HBV nuclei(t)side analogues to suppress HBV replication and to the application of universal HBV vaccination programs.Further changes are expected during the severe acute respiratory syndrome coronavirus-2 pandemic,unfortunately towards increased endemicity due to the focus of healthcare towards coronavirus disease 2019 and the consequently lower possibility of screening and access to treatments,lower care for patients with severe liver diseases and a reduced impulse to the HBV vaccination policy. 展开更多
关键词 hepatitis b virus/hepatitis delta virus SARS-CoV-2 COVID-19 hepatitis delta virus infection hepatitis D hepatitis delta virus epidemiology
下载PDF
Hepatitis B virus infection and the risk of hepatocellular carcinoma 被引量:25
4
作者 Ya-Jun Tan 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第44期4853-4857,共5页
Epidemiological studies have provided overwhelming evidence for a causal role of chronic hepatitis B virus(HBV) infection in the development of hepatocellular carcinoma(HCC).However,the pathogenesis of HBV infection a... Epidemiological studies have provided overwhelming evidence for a causal role of chronic hepatitis B virus(HBV) infection in the development of hepatocellular carcinoma(HCC).However,the pathogenesis of HBV infection and carcinogenesis of HBV-associated HCC are still elusive.This review will summarize the current knowledge on the mechanisms involved in HBV-related liver carcinogenesis.The role of HBV in tumor formation appears to be complex,and may involve both direct and indirect mechanisms.Integration of HBV DNA into the host genome occurs at early steps of clonal tumor expansion,and it has been shown to enhance the host chromosomal instability,leading to large inverted duplications,deletions and chromosomal translocations.It has been shown that the rate of chromosomal alterations is increased significantly in HBV-related tumors.Prolonged expression of the viral regulatory HBV x protein may contribute to regulating cellular transcription,protein degradation,proliferation,and apoptotic signaling pathways,and it plays a critical role in the development of hepatocellular carcinoma. 展开更多
关键词 Hepatocellular carcinoma hepatitis b virus infection hepatitis b virus genotypic variations hepatitis b virus x protein
下载PDF
Hepatitis B virus pre-S2 start codon mutations in Indonesian liver disease patients 被引量:3
5
作者 Andi Utama Marlinang Diarta Siburian +11 位作者 Ismail Fanany Mariana Destila Bayu Intan Rama Dhenni Tri Shinta Kurniasih Syafruddin AR Lelosutan Wenny Astuti Achwan Nasrul Zubir Arnelis Benyamin Lukito Irawan Yusuf Laurentius Adrianus Lesmana Ali Sulaiman 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第38期5418-5426,共9页
AIM: To identify the prevalence of pre-S2 start codon mutations and to assess their association with liver disease progression. METHODS: The mutations were identified by direct sequencing from 73 asymptomatic carriers... AIM: To identify the prevalence of pre-S2 start codon mutations and to assess their association with liver disease progression. METHODS: The mutations were identified by direct sequencing from 73 asymptomatic carriers, 66 chronic hepatitis (CH), 66 liver cirrhosis (LC) and 63 hepatocellular carcinoma (HCC) patients. Statistical significances were determined using Fisher's exact test, χ 2 test, and t -test analyses whenever appropriate. Pre-S mutation as a risk factor for advanced liver disease was estimated by unconditional logistic regression model adjusted with age, sex, and hepatitis B e antigen (HBeAg). P < 0.05 was considered significant. RESULTS: Mutation of the hepatitis B virus (HBV) pre-S2 start codon was found in 59 samples from 268 subjects (22.0%), with higher prevalence in patients with cirrhosis 27/66 (40.9%) followed by HCC 18/63 (28.6%), chronic hepatitis 12/66 (18.2%) and asymptomatic carriers 2/73 (2.7%) (P < 0.001). Logistic regression analysis showed that pre-S2 start codon mutation was an independent factor for progressive liver disease. Other mutations, at T130, Q132, and A138, were also associated with LC and HCC, although this was not statistically significant when adjusted for age, sex, and HBeAg. The prevalence of pre-S2 start codon mutation was higher in HBV/B than in HBV/C (23.0% vs 19.1%), whilst the prevalence of T130, Q132, and A138 mutation was higher in HBV/C than in HBV/B. The prevalence of pre-S2 start codon mutation was higher in LC (38.9%) and HCC (40.0%) than CH (5.6%) in HBeAg(+) group, but it was similar between CH, LC and HCC in HBeAg(-) group. CONCLUSION: Pre-S2 start codon mutation was higher in Indonesian patients compared to other Asian countries, and its prevalence was associated with advanced liver disease, particularly in HBeAg(+) patients. 展开更多
关键词 hepatitis b virus Pre-S2 start codon Liver disease hepatitis b e antigen seroconversion Indonesia
下载PDF
Direct antiviral agents in hepatitis C virus related liver disease:Don’t count the chickens before they’re hatched
6
作者 Stella Compagnoni Erica Maria Bruno +2 位作者 Giorgio Madonia Marco Cannizzaro Salvatore Madonia 《World Journal of Gastroenterology》 SCIE CAS 2021年第21期2771-2783,共13页
Since molecules with direct-acting antiviral(DAA)became available,the landscape of the treatment of hepatitis C virus(HCV)infection has completely changed.The new drugs are extremely effective in eradicating infection... Since molecules with direct-acting antiviral(DAA)became available,the landscape of the treatment of hepatitis C virus(HCV)infection has completely changed.The new drugs are extremely effective in eradicating infection,and treatment is very well tolerated with a duration of 8-12 wk.This review aims to report the outstanding clinical benefits of DAA and to highlight their critical disadvantages,identifying some clinically relevant hot topics.First,do the rates of virological response remain as high when patients with more advanced cirrhosis are considered?Large studies have shown slightly lower but still satisfactory rates of response in these patients.Nevertheless,modified schedules with an extended treatment duration and use of ribavirin may be necessary.Second,does the treatment of HCV infection affect the risk of occurrence and recurrence of liver cancer?Incidence is reduced after viral eradication but remains high enough to warrant periodic surveillance for an early diagnosis.In contrast,the risk of recurrence seems to be unaffected by viral clearance;however,DAA treatment improves survival because of the reduced risk of progression of liver disease.Third,can HCV treatment also have favorable effects on major comorbidities?HCV eradication is associated with a reduced incidence of diabetes,an improvement in glycemic control and a decreased risk of cardiovascular events;nevertheless,a risk of hypoglycemia during DAA treatment has been reported.Finally,is it safe to treat patients with HCV/hepatitis B virus(HBV)coinfection?In this setting,HCV is usually the main driver of viral activity,while HBV replication is suppressed.Because various studies have described HBV reactivation after HCV clearance,a baseline evaluation for HBV coinfection and a specific follow-up is mandatory. 展开更多
关键词 hepatitis C virus Direct antiviral activity Advanced cirrhosis Liver cancer Diabetes mellitus hepatitis C virus/hepatitis b virus coinfection
下载PDF
DUCK HEPATITIS B VIRUS DNA WITHIN HEPATIC MULTICENTRIC CANCER AND/OR METASTATIC CANCER
7
作者 杨广笑 王全颖 +3 位作者 金友南 迟宝荣 李家敏 叶维法 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1992年第1期9-16,共8页
Duck hepatitis B vims (DHBV) DNA was detected in different tumorous nodules of ducks with hepatic multicentric cancer or intrahepatic metastasis by Southern blot technique. Among 7 ducks with hepatocellular carcinoma ... Duck hepatitis B vims (DHBV) DNA was detected in different tumorous nodules of ducks with hepatic multicentric cancer or intrahepatic metastasis by Southern blot technique. Among 7 ducks with hepatocellular carcinoma of multiple tumor nodules, the hybridization pattern of Integrated DHBV DNA In different tumorous nodules was identical in 3 cases and different in 2 cases. One case showed a similar hybridization pattern in two tumorous nodules and other one was negative tor DHBV DNA. Integrated DHBV DNA was also identified in a metastatic lung cancer of ducks with hepatocellular carcinoma. The hybridization pattern of metastasis of lungs was as the some as that in primary hepatocellular carcinoma. The same discrete hybridization bands In the different tumorous nodules indicate that these nodules might arise from one transformed cell. The different hybridization patterns In various tumorous nodules show that these tumorous nodules might arise from various transformed cells. The results suggest that the hybridization pattern of different nodules of hepatocellular carcinoma with viral DNA probe could make a cell clone origin marker of tumor nodule to differentiate hepatic multlcentric cancer from Intrahepatic metastatic cancer. 展开更多
关键词 DNA DUCK hepatitis b virus DNA WITHIN HEPATIC MULTICENTRIC CANCER AND/OR METASTATIC CANCER DHbV
下载PDF
Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings
8
作者 Zeinab Nabil Ahmed Said Manal Hamdy El-Sayed 《World Journal of Hepatology》 2022年第7期1333-1343,共11页
The global burden of hepatitis B virus(HBV)and hepatitis C virus(HCV)infections and coinfection represents a major public health concern,particularly in resource-limited settings.Elimination of HCV by 2030 has become ... The global burden of hepatitis B virus(HBV)and hepatitis C virus(HCV)infections and coinfection represents a major public health concern,particularly in resource-limited settings.Elimination of HCV by 2030 has become foreseeable,with effective direct-acting antiviral oral therapies and the availability of affordable generics in low-and-middle-income countries(LMICs).However,access to oral nucleos(t)ide therapy for HBV remains critical and is limited outside the existing global HIV program platforms despite affordable prices.Prevention of mother-to-child transmission of HBV through scaling up of birth dose implementation in LMICs is essential to achieve the 2030 elimination goal.Most individuals living with HBV and/or HCV in resource-limited settings are unaware of their infection,and with improved access to medications,the most significant barrier remains access to affordable diagnostics and preventive strategies.The coronavirus disease 2019 pandemic interrupted hepatitis elimination programs,albeit offered opportunities for improved diagnostic capacities and raised political awareness of the critical need for strengthening health care services and universal health coverage.This review underpins the HBV and HCV management challenges in resource-limited settings,highlighting the current status and suggested future elimination strategies in some of these countries.Global efforts should continue to improve awareness and political commitment.Financial resources should be secured to access and implement comprehensive strategies for diagnosis and linkage to care in resource-constrained settings to fulfill the 2030 elimination goal. 展开更多
关键词 hepatitis b virus/hepatitis C virus Chronic hepatitis Resource-limited settings HbV and HCV elimination
下载PDF
Theoretical basis of a beneficial role for vitamin D in viral hepatitis 被引量:3
9
作者 Khanh vinh quoc Luong Lan Thi Hoàng Nguyen 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第38期5338-5350,共13页
Abnormal bone metabolism and dysfunction of the calcium-parathyroid hormone-vitamin D axis have been reported in patients with viral hepatitis. Some studies suggested a relationship between vitamin D and viral hepatit... Abnormal bone metabolism and dysfunction of the calcium-parathyroid hormone-vitamin D axis have been reported in patients with viral hepatitis. Some studies suggested a relationship between vitamin D and viral hepatitis. Genetic studies have provided an opportunity to identify the proteins that link vitamin D to the pathology of viral hepatitis (i.e., the major histocompatibility complex class Ⅱ molecules, the vitamin D receptor, cytochrome P 450 , the renin-angiotensin system, apolipoprotein E, liver X receptor, toll-like receptor, and the proteins regulated by the Sp1 promoter gene). Vitamin D also exerts its effects on viral hepatitis via non-genomic factors, i.e., matrix metalloproteinase, endothelial vascular growth factor, prostaglandins, cyclooxygenase-2, and oxidative stress. In conclusion, vitamin D could have a beneficial role in viral hepatitis. Calcitriol is best used for viral hepatitis because it is the active form of the vitamin D 3 metabolite. 展开更多
关键词 Calcitriol hepatitis hepatitis b virus hepatitis C virus Vitamin D
下载PDF
Impact of comorbidities on the severity of chronic hepatitis B at presentation 被引量:8
10
作者 Evangelista Sagnelli Tommaso Stroffolini +4 位作者 Alfonso Mele Michele Imparato Caterina Sagnelli Nicola Coppola Piero Luigi Almasio 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第14期1616-1621,共6页
AIM:To evaluate the clinical relevance of each cofactor on clinical presentation of chronic hepatitis B.METHODS:Out of 1366 hepatitis B surface antigen(HBsAg) positive subjects consecutively observed in 79 Italian hos... AIM:To evaluate the clinical relevance of each cofactor on clinical presentation of chronic hepatitis B.METHODS:Out of 1366 hepatitis B surface antigen(HBsAg) positive subjects consecutively observed in 79 Italian hospitals,53(4.3%) showed as the only cofactor hepatitis D virus(HDV) infection [hepatitis B virus(HBV)/HDV group],130(9.5%) hepatitis C virus(HCV)(group HBV/HCV),6(0.4%) human immunodeficiencyvirus(HIV)(group HBV/HIV),138(10.2%) alcohol abuse(group HBV/alcohol);109(8.0%) subjects had at least two cofactors and 924 were in the cofactor-free(CF) group.RESULTS:Compared with patients in group CF those in group HBV/alcohol were older and more frequently had cirrhosis(P < 0.001),those in group HBV/HDV were younger(P < 0.001),more frequently resided in the south of the country and had cirrhosis(P <0.001),those in group HBV/HCV were older(P < 0.001) and more frequently had cirrhosis(P < 0.001).These cofactors were all independent predictors of liver cirrhosis in HBsAg positive patients.Multivariate analysis showed that an older age [odds ratio(OR) 1.06,95% CI:1.05-1.08],alcohol abuse with more than 8 drinks daily(OR 2.89,95% CI:1.81-4.62) and anti-HDV positivity(OR 3.48,95% CI:2.16-5.58) are all independently associated with liver cirrhosis.This association was found also for anti-HCV positivity in univariate analysis,but it was no longer associated(OR 1.23,95% CI:0.84-1.80) at multivariate analysis.CONCLUSION:Older age,HDV infection and alcohol abuse are the major determinants of severe liver disease in chronic HBV infection,while HCV replication plays a lesser role in the severity of hepatic damage. 展开更多
关键词 Chronic hepatitis b hepatitis b virus/hepatitis D virus dual infection hepatitis b virus/hepatitis C virus dual infection Alcohol abuse
下载PDF
Management of chronic hepatitis B in pregnancy 被引量:16
11
作者 Guo-Rong Han Chuan-Lu Xu +1 位作者 Wei Zhao Yong-Feng Yang 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第33期4517-4521,共5页
Pregnancy associated with chronic hepatitis B (CHB) is a common and important problem with unique challenges. Pregnant women infected with CHB are different from the general population, and their special problems need... Pregnancy associated with chronic hepatitis B (CHB) is a common and important problem with unique challenges. Pregnant women infected with CHB are different from the general population, and their special problems need to be considered: such as the effect of hepatitis B virus (HBV) infection on the mother and fetus, the effect of pregnancy on replication of the HBV, whether mothers should take HBV antiviral therapy during pregnancy, the effect of these treatments on the mother and fetus, how to carry out immunization of neonates, whether it can induce hepatitis activity after delivery and other serious issues. At present, there are about 350 million individuals with HBV infection worldwide, of which 50% were infected during the perinatal or neonatal period, especially in HBV-endemic countries. Currently, the rate of HBV infection in thechild-bearing age group is still at a high level, and the infection rate is as high as 8.16%. Effective prevention of mother-to-child transmission is an important means of reducing the global burden of chronic HBV infection. Even after adopting the combined immunization measures, there are still 5%-10% of babies born with HBV infection in hepatitis B e antigen positive pregnant women. As HBV perinatal transmission is the main cause of chronic HBV infection, we must consider how to prevent this transmission to reduce the burden of HBV infection. In this population of chronic HBV infected women of childbearing age, specific detection, intervention and follow-up measures are particularly worthy of attention and discussion. 展开更多
关键词 Chronic hepatitis b hepatitis b virus Mother-to-child transmission Perinatal transmission Pregnancy Vertical transmission Antiviral therapy
下载PDF
Hepatitis B virus S gene mutants in infants infected despite immunoprophylaxis 被引量:4
12
作者 朱启镕 吕晴 +2 位作者 俞蕙 段恕诚 熊思东 《Chinese Medical Journal》 SCIE CAS CSCD 2001年第4期16-18,102,共4页
Objective To assess the correlation between hepatitis B virus (HBV) surface gene mutant infection and hepatitis B (HB) vaccination failure Methods Using sera from 106 infants who were born to HBV carrier mothers a... Objective To assess the correlation between hepatitis B virus (HBV) surface gene mutant infection and hepatitis B (HB) vaccination failure Methods Using sera from 106 infants who were born to HBV carrier mothers and failed in HB immunoprophylaxis, HBV S gene was amplified by PCR, transferred to nylon membranes for Southern blots, and then hybridized with oligonucleotide probes Eleven of non hybridizing samples were used for DNA sequencing Results 93 4% (99/106) of the samples were HBV DNA positive, and 30 3% (30/99) failed to hybridize with at least one of the four probes DNA sequencing confirmed that 10 of the 11 samples had an S gene mutation with amino acid (aa) change The identified mutants included nucleotide (nt) 546T→A(aa131N→T), nt531T→C (aa126I→T), nt491A→C (aa113T→P), nt491T→A (aa113S→T), nt533C→A (aa127P→T), nt581T→A (aa143S→T), nt636A→T (aa161Y→F), and nt679A→C (aa175L→F) The sequence in one mother infant pair was completely the same, with mutations at aa131 and aa161 Conclusions The prevalence of HBV surface mutants is about 30% in the children failing in HB vaccination HBV mutants can infect infants by maternal infant transmission 展开更多
关键词 hepatitis b virus · S gene mutant · hepatitis b vaccine
原文传递
A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection 被引量:28
13
作者 姚光弼 王宝恩 +2 位作者 崔振宇 姚集鲁 曾民德 《Chinese Medical Journal》 SCIE CAS CSCD 1999年第5期3-7,共5页
Objective To evaluate the effect of lamivudine on the loss of serum he patitis B virus (HBV) DNA, HBeAg/antiHBe seroconversion and ALT levels in chron ic hepatitis B patients and its safety profile and tolerance comp... Objective To evaluate the effect of lamivudine on the loss of serum he patitis B virus (HBV) DNA, HBeAg/antiHBe seroconversion and ALT levels in chron ic hepatitis B patients and its safety profile and tolerance compared with place bo.Methods Four hundred and twenty nine patients with chronic HBV infecti on as defined by positive HBsAg, HBeAg and HBV DNA were enrolled and randomized into lamivudine and placebo groups. Three hundred and twenty two patients recei ved lamivudine 100?mg daily and 107 patients received placebo treatment for 12 weeks. Then, all patients were offered a further 9 month open label lamivudine treatment. The efficacy and safety were evaluated with clinical, biochemical, hematological and virological parameters. Results During the 12 week treatment period, 92.2% of lamivudine t reate d patients became HBV DNA negative (below 1.6?pg/ml) compared with only 14.1% o f those receiving placebo (P<0.01). At the end of 12 week, the sust ained negative rate for HBV DNA in the lamivudine treated group was 78.5% compar ed with the placebo group (11.1%; P< 0.01). There was a trend to a high proportion of patients treated with lamivudine to lose HBeAg (8.1%) and d evelop antiHBe (10.2%) than treated with placebo (5.3% and 6.4% respectively), b ut this difference was not statistically significant. Patients with elevated AL T levels at baseline became normal in 60.3% of the lamivudine treated group comp ared with the placebo group where only 27.5% were normal (P<0.01). L amivudine was well tolerated in a dose of (100?mg daily) and the overall incide nce of adverse events was similar to that of the placebo. Conclusions Lamivudine (100 mg daily) is very effective in the inhibiti on of HBV replication, indicated by the rapid loss of serum HBV DNA, and often acco mpanied by a decrease of serum ALT levels. Lamivudine is well tolerated withou t severe adverse events during treatment. 展开更多
关键词 lamivudine · hepatitis b virus · chronic hepatitis b
原文传递
LONG-TERM IMMUNOGENICITY AND EFFICACY OF RECOMBINANT YEAST DERIVED HEPATITIS B VACCINE FOR INTERRUPTION OF MOTHER-INFANT TRANSMISSION OF HEPATITIS B VIRUS
14
作者 朱启镕 顾新焕 +1 位作者 段恕诚 徐华芳 《Chinese Medical Journal》 SCIE CAS CSCD 1994年第12期37-40,共4页
Recombinant DNA Yeast-Derived Hepatitis B Vaccine (RYHB vaccine) is comparable to and can replace Plasma-Derived Hepatitis B Vaccine (PHB vaccine) for the prevention of mother-nfant transmission of hepatitis B virus (... Recombinant DNA Yeast-Derived Hepatitis B Vaccine (RYHB vaccine) is comparable to and can replace Plasma-Derived Hepatitis B Vaccine (PHB vaccine) for the prevention of mother-nfant transmission of hepatitis B virus (HBV), but the duration of immune efficacy of RYHB vaccine is not clear. This study indicates the long-term efficacy for the prevention of mother-infant transmission of HBV. One hundred and six neonates born to HBsAg-arrier mothers with HBeAg positive were randomly divided into two groups, one receiving 20 μg per dose of RYHB vaccine and the another receiving 20 μg per dose of PHB vaccine on the day of birth, at 1 month and at 6 months (three times). Physical examination and blood tests were performed for all infants at 6, 12, 24, 36, 48 and 60 months of age. The results showed that the protective efficacies at 6, 12, 24, 36, 48 and 60 months were 67%, 75%, 63%, 62%, 57% and 56%, respectively for the RYHB vaccine group and 58%, 76%, 51%, 41%, 24% and 18%, respectively for the PHB vaccine group. The protective efficacy was notably significant in the last two years. The study indicates that the duration of protective efficacy is over 5 years with RYHB vaccine, being longer than that of PHB vaccine. These recipients of RYHB vaccine showed no side effects, and the vaccine is regarded as safe and effective. 展开更多
关键词 PHb LONG-TERM IMMUNOGENICITY AND EFFICACY OF RECOMbINANT YEAST DERIVED hepatitis b VACCINE FOR INTERRUPTION OF MOTHER-INFANT TRANSMISSION OF hepatitis b virus HbV HbsAg
原文传递
Evaluation of Helicobacter pylori Infection in Patients with Chronic Hepatic Disease 被引量:12
15
作者 Ju Huang Jun Cui 《Chinese Medical Journal》 SCIE CAS CSCD 2017年第2期149-154,共6页
Background: The ^13C urea breath test (^13C-UBT) is the gold standard for detecting Helicobacterpylori infection. H. pylori pathogenesis in patients with hepatitis B virus (HBV) and related diseases remains obscu... Background: The ^13C urea breath test (^13C-UBT) is the gold standard for detecting Helicobacterpylori infection. H. pylori pathogenesis in patients with hepatitis B virus (HBV) and related diseases remains obscure. We used ^13C-UBT to detect H. p.vlori infection in patients with chronic HBV infection, HBV-related cirrhosis, HBV-related hepatic carcinoma, and other chronic hepatic diseases. Methods: A total of 131 patients with chronic hepatitis B (HB), 179 with HBV-related cirrhosis, 103 with HBV-related hepatic carcinoma, 45 with HBV-negative hepatic carcinoma, and 150 controls were tested for H. pylori infection using ^13C-UBT. We compared H. pylori infection rate, liver function, complications of chronic hepatic disease, serum HBV-DNA, serum alpha-fetoprotein (AFP), and portal hypertensive gastropathy (PHG) incidence among groups. Results: HBV-related cirrhosis was associated with the highest H. pylori infection rate (79.3%). H. pylori infection rate in chronic HB was significantly higher than in the HBV-negative hepatic carcinoma and control groups (P 〈 0.001 ). 11. pylori infection rate in patients with HBV-DNA ≥10^3 copies/ml was significantly higher than in those with HBV-DNA 〈103 copies/ml (76.8% vs. 52.4%, P 〈 0.001). Prothrombin time (21.3 ± 3.5 s vs. 18.8 ±4.3 s), total bilirubin (47.3±12.3 μmol/L vs. 26.6±7.9 μmol/L), aspartate aminotransferase ( 184.5 ±37.6 U/L vs. 98.4 ± 23.5 U/L), blood ammonia (93.4 ± 43.6 μmol/L vs. 35.5 ± 11.7 μmol/L), and AFP (203.4±62.6 μg/L vs. 113.2± 45.8 μg/L) in the ^13C-UBT-positive group were significantly higher than in the ^13C-UBT-negative group (P 〈 0.01). The incidence rates of esophageal fundus variceal bleeding (25.4% vs. 16.0%), ascites (28.9% vs. 17.8%), and hepatic encephalopathy (24.8% vs. 13.4%) in the ^13C-UBT-positive group were significantly higher than in the 13C-UBT-negative group (P 〈 0.01 ). The percentages of patients with liver function in Child-Pugh Grade C (29.6% vs. 8.1%) and PHG (43.0% vs. 24.3%) in the ^13C-UBT-positive group were significantly higher than in the ^13C-UBT-negative group (P 〈 0.05). Conclusions: It is possible that H. pylori infection could increase liver damage caused by HBV. 1t. pylori eradication should be performed in patients with complicating H. pylori infection to delay hepatic disease progression. 展开更多
关键词 Helicobacter Pylori Infection hepatitis b virus hepatitis b virus-related Cirrhosis hepatitis b virus-related HepaticCarcinoma: Urea breath Test
原文传递
NKT cells in liver diseases 被引量:10
16
作者 Shasha Zhu Huimin Zhang Li Bai 《Frontiers of Medicine》 SCIE CAS CSCD 2018年第3期249-261,共13页
Natural killer T cells are innate-like and tissue-resident lymphocytes, which recognize lipid antigens and are enriched in the liver. Natural killer T cells play important roles in infections, tumors, autoimmune disea... Natural killer T cells are innate-like and tissue-resident lymphocytes, which recognize lipid antigens and are enriched in the liver. Natural killer T cells play important roles in infections, tumors, autoimmune diseases, and metabolic diseases. In this study, we summarize recent findings on biology of natural killer T cells and their roles in hepatitis B virus and hepatitis C virus infection, autoimmune liver diseases, alcoholic liver disease, nonalcoholic fatty liver disease, and hepatocellular carcinoma. Controversial results from previous studies are discussed, and indicate the dynamic alteration in the role of natural killer T cells during the progression of liver diseases, which might be caused by changes in natural killer T subsets, factors skewing cytokine responses, and intercellular crosstalk between natural killer T cells and CDld-expressing cells or bystander cells. 展开更多
关键词 natural killer T cells hepatitis b virus and hepatitis C virus infection autoimmune liver diseases alcoholic liverdisease nonalcoholic fatty liver disease hepatocellular carcinoma
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部